Skip to main content

Research Repository

Advanced Search

Browse


Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ (2022)
Journal Article
Miligy, I. M., Toss, M. S., Gorringe, K. L., Ellis, I. O., Green, A. R., & Rakha, E. A. (2022). Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. Pathobiology, 1-11. https://doi.org/10.1159/000522244

Aurora Kinase A (AURKA/STK15) has a role in centrosome duplication and is a regulator of mitotic cell proliferation. It is over-expressed in breast cancer and other cancers, however; its role in ductal carcinoma in situ (DCIS) remains to be defined.... Read More about Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer (2022)
Journal Article
Saunus, J. M., De Luca, X. M., Northwood, K., Raghavendra, A., Hasson, A., Mccart Reed, A. E., …Lakhani, S. R. (2022). Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. npj Breast Cancer, 8, Article 57. https://doi.org/10.1038/s41523-022-00425-x

Intratumoral heterogeneity is caused by genomic instability and phenotypic plasticity, but how these features co-evolve remains unclear. SOX10 is a neural crest stem cell (NCSC) specifier and candidate mediator of phenotypic plasticity in cancer. We... Read More about Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.

The Characteristics and Clinical Significance of Atypical Mitosis in Breast Cancer (2022)
Journal Article
Lashen, A., Toss, M. S., Alsaleem, M., Green, A. R., Mongan, N. P., & Rakha, E. (2022). The Characteristics and Clinical Significance of Atypical Mitosis in Breast Cancer. Modern Pathology, https://doi.org/10.1038/s41379-022-01080-0

Atypical mitosis is considered a feature of malignancy, however, its significance in breast cancer (BC) remains elusive. Here, we aimed to assess the clinical value of atypical mitoses in BC and to explore their underlying molecular features. Atypica... Read More about The Characteristics and Clinical Significance of Atypical Mitosis in Breast Cancer.

Standardization of the tumor-stroma ratio scoring method for breast cancer research (2022)
Journal Article
Hagenaars, S. C., Vangangelt, K. M. H., Van Pelt, G. W., Karancsi, Z., Tollenaar, R. A. E. M., Green, A. R., …Mesker, W. E. (2022). Standardization of the tumor-stroma ratio scoring method for breast cancer research. Breast Cancer Research and Treatment, 193, 545-553. https://doi.org/10.1007/s10549-022-06587-3

Purpose: The tumor-stroma ratio (TSR) has repeatedly proven to be correlated with patient outcomes in breast cancer using large retrospective cohorts. However, studies validating the TSR often show variability in methodology, thereby hampering compar... Read More about Standardization of the tumor-stroma ratio scoring method for breast cancer research.

Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion (2022)
Journal Article
Aljohani, A. I., Toss, M. S., El-Sharawy, K. A., Mirza, S., Ball, G. R., Green, A. R., & Rakha, E. (2022). Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion. American Journal of Cancer Research, 12(2), 469-489

Lymphovascular invasion (LVI) is a key step in breast cancer (BC) metastasis. Targeting the molecular drivers of LVI can improve BC patients’ management. However, the underlying molecular mechanisms of LVI are complex and interconnected with various... Read More about Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion.

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer (2022)
Journal Article
Kariri, Y., Toss, M. S., Alsaleem, M., Elsharawy, K. A., Joseph, C., Mongan, N. P., …Rakha, E. A. (2022). Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer. Breast Cancer Research and Treatment, 192(3), 529-539. https://doi.org/10.1007/s10549-022-06531-5

Background The Ubiquitin-conjugating enzyme 2C (UBE2C) is essential for the ubiquitin–proteasome system and is involved in cancer cell migration and apoptosis. This study aimed to determine the prognostic value of UBE2C in invasive breast cancer (BC... Read More about Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer (2021)
Journal Article
Althobiti, M., El-Sharawy, K. A., Joseph, C., Aleskandarany, M., Toss, M. S., Green, A. R., & Rakha, E. A. (2021). Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. Breast Cancer Research and Treatment, 189(3), 621–630. https://doi.org/10.1007/s10549-021-06336-y

Purpose The outcome of the luminal oestrogen receptor-positive (ER +) subtype of breast cancer (BC) is highly variable and patient stratification needs to be refined. We assessed the prognostic significance of oestrogen-regulated solute carrier fami... Read More about Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer.

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer (2021)
Journal Article
Masisi, B. K., El Ansari, R., Alfarsi, L., Craze, M. L., Jewa, N., Oldfield, A., …Green, A. R. (2021). The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. Cancers, 13(16), Article 3963. https://doi.org/10.3390/cancers13163963

Glutamine metabolism has a key role in the regulation of uncontrolled tumour growth. This study aimed to evaluate the expression and prognostic significance of glutaminase in luminal breast cancer (BC). The glutaminase isoforms (GLS/GLS2) were assess... Read More about The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ (2021)
Journal Article
Al-Kawaz, A., Miligy, I. M., Toss, M. S., Mohammed, O. J., Green, A. R., Madhusudan, S., & Rakha, E. A. (2021). The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. Breast Cancer Research and Treatment, 188(1), 53-63. https://doi.org/10.1007/s10549-021-06271-y

Background Impaired DNA repair mechanism is one of the cancer hallmarks. Flap Endonuclease 1 (FEN1) is essential for genomic integrity. FEN1 has key roles during base excision repair (BER) and replication. We hypothesised a role for FEN1 in breast c... Read More about The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in oestrogen receptor-positive breast cancer (2021)
Journal Article
Alfarsi, L. H., Ansari, R. E., Craze, M. L., Mohammed, O. J., Masisi, B. K., Ellis, I. O., …Green, A. R. (in press). SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in oestrogen receptor-positive breast cancer. Breast Cancer Research and Treatment,

Purpose: Identification of effective biomarkers for the benefit of endocrine treatment and understanding the molecular pathways that contribute to the development of resistance are of crucial importance to the management of luminal breast cancer. The... Read More about SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in oestrogen receptor-positive breast cancer.

Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray (2020)
Journal Article
Parks, R. M., Albanghali, M. A., Syed, B. M., Green, A. R., Ellis, I. O., & Cheung, K. L. (2021). Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray. Breast Cancer Research and Treatment, 185(3), 647-655. https://doi.org/10.1007/s10549-020-06023-4

© 2020, The Author(s). Purpose: Prediction of response to primary endocrine therapy (PET) in older women is based on measurement of oestrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor (HER)-2. This study uses a uniq... Read More about Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray.

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer (2020)
Journal Article
Elsharawy, K. A., Althobiti, M., Mohammed, O. J., Aljohani, A. I., Toss, M. S., Green, A. R., & Rakha, E. (2021). Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 185(3), 615-627. https://doi.org/10.1007/s10549-020-05999-3

Purpose Nucleolar protein 10 (NOP10) is required for ribosome biogenesis and telomere maintenance and plays a key role in carcinogenesis. This study aims to evaluate the clinical and prognostic significance of NOP10 in breast cancer (BC). Methods... Read More about Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer.

The prognostic significance of Interferon Stimulated Gene 15 (ISG15) in invasive breast cancer (2020)
Journal Article
Kariri, Y., Alsaleem, M., Joseph, C., Alsaeed, S., Aljohani, A., Shiino, S., …Rakha, E. A. (2021). The prognostic significance of Interferon Stimulated Gene 15 (ISG15) in invasive breast cancer. Breast Cancer Research and Treatment, 185(2), 293–305. https://doi.org/10.1007/s10549-020-05955-1

Background Lymphovascular invasion (LVI) is a prognostic factor in early-stage invasive breast cancer (BC). Through bioinformatics, data analyses of multiple BC cohorts revealed the positive association between interferon-stimulated gene 15 (ISG15... Read More about The prognostic significance of Interferon Stimulated Gene 15 (ISG15) in invasive breast cancer.

The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer (2020)
Journal Article
Elsharawy, K. A., Mohammed, O. J., Aleskandarany, M. A., Hyder, A., El-Gammal, H. L., -Dobara, A., …Rakha, E. A. (2020). The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer. British Journal of Cancer, 123, 1543–1552. https://doi.org/10.1038/s41416-020-01045-7

Background Hypertrophy of the nucleolus is a distinctive cytological feature of malignant cells and corresponds to aggressive behaviour. This study aimed to identify the key gene associated with nucleolar prominence (NP) in breast cancer (BC) and... Read More about The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer.

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets (2020)
Journal Article
Kurozumi, S., Alsaleem, M., Monteiro, C. J., Bhardwaj, K., Joosten, S. E., Fujii, T., …Johnston, S. J. (2020). Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Research, 22, https://doi.org/10.1186/s13058-020-01324-4

© 2020 The Author(s). Background: Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tractable... Read More about Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ (2020)
Journal Article
Miligy, I. M., Toss, M. S., Shiino, S., Oni, G., Syed, B. M., Khout, H., …Rakha, E. A. (2020). The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. British Journal of Cancer, 123, 1513–1520. https://doi.org/10.1038/s41416-020-1023-3

Background: Oestrogen receptor (ER) in invasive breast cancer (BC) predicts response to endocrine therapy (ET) and provides prognostic value. In this study, we investigated the value of ER expression in ductal carcinoma in situ (DCIS) in terms of out... Read More about The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.

Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome (2020)
Journal Article
Parks, R. M., Albanghali, M., Syed, B. M., Green, A. R., Ellis, I. O., & Cheung, K. L. (2020). Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome. Cancers, 12(8), https://doi.org/10.3390/cancers12082067

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. The majority of biological profiling studies use surgical excision (SE) samples, excluding patients receiving nonsurgical and neoadjuvant therapy. We propose using core needle biopsy (CNB) for... Read More about Biology of oestrogen-receptor positive primary of core needle biopsy samples and correlation with clinical outcome.

IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis (2020)
Journal Article
Siersbaek, R., Scabia, V., Nagarajan, S., Chernukhin, I., Papachristou, E. K., Broome, R., …Carroll, J. S. (2020). IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis. Cancer Cell, 38(3), 412-423.e9. https://doi.org/10.1016/j.ccell.2020.06.007

The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives me... Read More about IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.